Accession Number:

ADB101195

Title:

Control of Hepatitis Virus Infections by New Methods

Descriptive Note:

Technical Report,01 Feb 1983,31 Jan 1984

Corporate Author:

BAYLOR COLL OF MEDICINE HOUSTON TX HOUSTON United States

Personal Author(s):

Report Date:

1984-01-31

Pagination or Media Count:

18.0

Abstract:

During the past contract year, we have continued our investigations with antiidiotype reagents that recognize a common idiotypic determinant on human anti-HBs molecules. Several important immunochemical parameters were established 1 Injection of anti-idiotype antibodies prior to HBsAg inoculation enhanced the anti-HBs response when compared to groups of mice given control antibodies before HBsAg. 2 Primarily IgG anti-HBs was induced if the anti-idiotype antibodies were given as an alum precipitate, whereas IgM anti-HBs was generated if the anti-idiotype antibodies were administered in a soluble form. 3 The anti-HBs response also was increased when antiidiotype antibodies were given in conjugation with a cyclic synthetic HBsAg peptide SPI which contains amino acid sequences 122-137. This anti-HBs response was comparable to a single injection of HBsAg. We also have induced anti-HBs by injecting anti-idiotype antibodies alone. The antiidiotype-induced anti-HBs expressed an interpsecies idiotype that is shared by human anti-HBs produced by natural infection with HBV. In addition, the anti-HBs recognized the group-specific a determinant of HBsAg. These data suggest the potential use of antiidiotypes as vaccines and immunopotentiators of the anti-HBs response. Studies also have been performed on the use of an HBsAg polypeptide vaccine in young adults. Finally, we have made a firm commitment from Baylor funds to continue our investigations with HBsAg synthetic peptides by purchasing an amino acid synthesizer.

Subject Categories:

Distribution Statement:

APPROVED FOR PUBLIC RELEASE